Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials

Author:

Mullol Joaquim1ORCID,Laidlaw Tanya M.2ORCID,Bachert Claus345ORCID,Mannent Leda P.6,Canonica G. Walter7ORCID,Han Joseph K.8,Maspero Jorge F.9ORCID,Picado Cesar10ORCID,Daizadeh Nadia11ORCID,Ortiz Benjamin12,Li Yongtao13,Ruddy Marcella14,Laws Elizabeth15,Amin Nikhil14ORCID

Affiliation:

1. Rhinology Unit & Smell Clinic, ENT Department Hospital ClínicIDIBAPSUniversitat de BarcelonaCIBERES Barcelona Catalonia Spain

2. Division of Allergy and Clinical Immunology Brigham and Women's Hospital, and Harvard Medical School Boston Massachusetts USA

3. Upper Airways Research Laboratory and Department of Otorhinolaryngology Ghent University Ghent Belgium

4. Division of ENT Diseases, CLINTEX Karolinska Institutet Stockholm Sweden

5. First Affiliated Hosptial Sun Yat‐sen University Guangzhou China

6. Global Clinical Development Sanofi, Chilly‐Mazarin France

7. Department of Biomedical Sciences Humanitas University, Personalized Medicine Asthma & Allergy Unit‐IRCCS Humanitas Research Hospital, Rozzano Milan Italy

8. Department of Otolaryngology & Head and Neck Surgery Eastern Virginia Medical School Norfolk Virginia USA

9. Allergy and Respiratory Medicine Fundación CIDEA Buenos Aires Argentina

10. Clinical & Experimental Respiratory Immunoallergy IDIBAPS, Universitat de Barcelona, CIBERES Barcelona Catalonia Spain

11. Biostatistics Sanofi Cambridge Massachusetts USA

12. Immunology and Allergy Medical Affairs Regeneron Pharmaceuticals, Inc. New York USA

13. Global Medical Affairs Respiratory Sanofi Bridgewater New Jersey USA

14. Clinical Sciences Global Development Regeneron Pharmaceuticals, Inc. Tarrytown New Jersey USA

15. Immunology and Inflammation Sanofi Bridgewater New Jersey USA

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3